Effect of Sars-cov-2 on Donor Oocyte Quality and Quantity, a Multicenter Retrospective Study.
Launched by NOVAFEM · Sep 28, 2022
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
This was a multicenter retrospective cohort study performed at the Centro de Fertilidad y Genetica Novafem, Bogota, Colombia, and Clinica de la Mujer - Medicina Reproductiva, Viña del Mar, Chile. The Ethics Committee approved the study protocol of both centers. Informed contents were obtained from patients for data collection with scientific use.
All donors who underwent COS for oocyte donation between January 1st, 2018 and July 31th, 2022 were screened for eligibility and followed up to September 18th, 2022.
Oocyte donation cycles were utilized because this model is an excellent choice f...
Gender
FEMALE
Eligibility criteria
- • Inclusion
- • Age: 18 - 32 Years
- • Body Mass Index between 18 and 26
- • AFC: Antral follicular count over 15 in total.
- • AMH: Anti-Mullerian hormone over 2.5
- • Signed consents.
- • Covid vaccines and infection information (for case group).
- Exclusion:
- • Egg donors with incomplete information of days of stimulation, average dose of gonadotropins, the number of retrieved oocytes, mature oocytes, fertilised oocytes and top-quality embryos obtained.
- • Familial genetic disorders.
- • Menstrual cycle disorders.
- • Polycystic ovary syndrome.
About Novafem
Novafem is a leading clinical trial sponsor dedicated to advancing women's health through innovative research and development. With a commitment to improving therapeutic options, Novafem focuses on conducting high-quality clinical trials that address unmet medical needs in areas such as reproductive health, menopause management, and hormonal therapies. The organization collaborates with healthcare professionals, regulatory bodies, and research institutions to ensure the safety and efficacy of its products, aiming to enhance the quality of life for women globally. Through rigorous scientific methodologies and patient-centered approaches, Novafem strives to deliver breakthrough solutions that empower women and promote their overall well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bogotá, , Colombia
Patients applied
Trial Officials
Jose A Moreno, PhD
Study Chair
Universitat Autonoma de Barcelona
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials